News

InCarda Therapeutics featured in Men’s Health

InCarda Therapeutics CEO Grace Colón was interviewed for this brief and informative piece on Atrial Fibrillation, The Hidden Heart Problem That's Claiming Men's Lives Now by Julie Stewart in the February 2021 edition of Men’s Health. Key points: “There’s a U-shaped curve with AFib—people who don’t exercise...

InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation

Ongoing Trial to Evaluate Optimal Dose Selected from Dose-Ranging Stage of the INSTANT Study for Rapid Conversion of Atrial Fibrillation to Normal Sinus Rhythm SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular...

Grace Colón Joins the First Rounders Podcast

Grace Colón joins the First Rounders Podcast (aired on 1/2/21). The conversation covers growing up in San Juan; her love musical theater; and how grad school at MIT guided her toward a career in entrepreneurship.  https://play.acast.com/s/naturebiotechnologypodcast/gracecolon...

InCarda Therapeutics to Present Preliminary Phase 2 Data at American Heart Association 2020 Scientific Sessions (Nov. 13-17, 2020)

On Friday, November 13 at 9:00am CT/10:00am ET, Dr. Harry Crijns, Clinical Electrophysiologist from Maastricht University Medical Center in the Netherlands, will present data from the open-label, dose-escalation Part A portion of InCarda’s multinational INSTANT Phase 2 clinical trial of InRhythm™ (flecainide for inhalation) in...

InCarda Therapeutics featured in Endpoints News

InCarda Therapeutics and our President & CEO Grace Colón were featured in a recent post on Endpoints News. The post highlights InCarda's Raise of $30 Million Through First Close of Series C Equity Financing. More information below: “This is especially exciting at a time when more...

InCarda Therapeutics featured in FierceBiotech News

InCarda Therapeutics and our President & CEO Grace Colón were featured in a recent post on Endpoints News. The post highlights InCarda's Raise of $30 Million Through First Close of Series C Equity Financing. More information below: “What we're doing is a completely new way of...